Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol

(2016) Knut Tore Lappegård et al.   ATHEROSCLEROSIS

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

Quality of life in patients treated with lipoprotein apheresis

(2016) Adrian Rosada et al.   Journal of Clinical Lipidology

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

(2015) Dean J. Kereiakes et al.   AMERICAN HEART JOURNAL

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

(2015) John J.P. Kastelein et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

(2015) Christopher P. Cannon et al.   EUROPEAN HEART JOURNAL

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

(2015) Harold Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

(2014) Eli M. Roth et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

(2008) A. Neil et al.   EUROPEAN HEART JOURNAL